Oct 24, 2024
Tessera Releases Promising Preclinical Data for Its In Vivo Gene Editing Technology, Showcasing Potential Treatments for Alpha-1 Antitrypsin Deficiency and Sickle Cell Disease. (Source)
Intellia Announces Positive Data from Phase 2 Trial of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema. (Source)
Precision BioSciences secures approval for its first-in-human trial, PBGENE-HBV, to treat chronic Hepatitis B. Gene-editing, chronic hepatitis B infection (Source)
Oct 22, 2024
Editas Medicine has made progress towards its 2024 goals, including achieving in vivo proof of concept for a potential treatment of sickle cell disease and beta-thalassemia. (Source)
Oct 21, 2024
Editas Medicine and Genevant Sciences have announced a strategic collaboration to develop novel mRNA-LNP gene editing therapeutics. Gene-editing, platform development, in-vivo therapeutics (Source)
Oct 07, 2024
Intellia Therapeutics has started a Phase 3 clinical trial to evaluate NTLA-2002, a CRISPR-based gene editing treatment for hereditary angioedema. (Source)
Sept 24, 2024
Health Canada grants marketing authorization to CASGEVY® (Vertex Pharmaceuticals) a groundbreaking CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia. (Source)
Lonza and Vertex Pharmaceuticals have announced a long-term global commercial supply agreement for CASGEVY® (exagamglogene autotemcel), the world’s first CRISPR/Cas9 gene-edited cell therapy. (Source)
Sept 17, 2024
Syntax Bio, a stem cell technology company with its origins at the University of Illinois Chicago, has raised $15 million in funding. (Source) Syntax Bio is a preclinical-stage biotech company overcoming the longstanding challenges in stem cell-derived therapies by directly controlling and accelerating cell differentiation.
New Scientific Study: A new genetic system allows for precise, sequential activation of genes. By removing a termination signal, Cas9-VPR protein activates transcription and cuts DNA, enabling a cascade of gene activations. This system can be used to program the differentiation of human stem cells. Syntax Bio. (Source)
Sept 16, 2024
Vertex and CRISPR Therapeutics’s CASGEVY® is finally treating sickle cell patients. (Source)
July 17, 2024
Ancilia Bio, a biotech firm using CRISPR, raised $4.2 million to develop bacterial therapies against viruses. (Source)
